Comparative effectiveness of interferons in relapsing–remitting multiple sclerosis: a meta-analysis of real-world studies

Abstract

In this comprehensive meta-analysis of real-world studies in RRMS, IFN-beta-1a IM, IFN-beta-1a SC and IFN-beta-1b SC had similar clinical profiles. When selecting an IFN, practitioners should consider observational data in their decision making process.

Exosome‐associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients

“…However, over the past 30 yr, various drugs able to modify the clinical course of the disease have been introduced into clinical practice. IFN-b represents an efficacious first-line treatment for the RRMS variant (5,6). IFNs are a group of endogenous glycoproteins endowed with immunomodulatory, antiviral, and antiproliferative properties.…”

Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System

“…For the patients with symptoms consistent with MS which is multiple in time and space, the management includes immunosuppressant and disease-modifying therapy (DMT),[51] and for the patients whose diagnoses not consistent with MS or NMOSD, treatment with immunosuppressant is a choice even though it is lack of evidence.Main DMTs: The US Food and Drug Administration approved DMTs for MS include 10 medications:[5181828384] (a)first line: Betaseron (interferon β-1b), Extavia (interferon β-1b), Rebif (interferon β-1a), Avonex (interferon β-1a), glatiramer acetate, dimethyl fumarate, teriflunomide; (b) second line: natalizumab; (c) third line: mitoxantrone. Currently, in China, the approved DMTs by the China Food and Drug Administration are Betaferon and Rebif.…”

“…Main DMTs: The US Food and Drug Administration approved DMTs for MS include 10 medications:[5181828384] (a)first line: Betaseron (interferon β-1b), Extavia (interferon β-1b), Rebif (interferon β-1a), Avonex (interferon β-1a), glatiramer acetate, dimethyl fumarate, teriflunomide; (b) second line: natalizumab; (c) third line: mitoxantrone. Currently, in China, the approved DMTs by the China Food and Drug Administration are Betaferon and Rebif.…”

Impacto orçamentário de natalizumabe para o tratamento em primeira linha da esclerose múltipla remitente-recorrente altamente ativa sob a perspectiva do sistema de saúde privado brasileiro

“…A taxa anualizada assumida de ocorrência de surtos para a população em geral com EMRR foi de 0,51 (Einarson et al, 2017). Já para a população com alta atividade da doença, foram assumidas duas diferentes taxas anualizadas: uma para a população em uso de natalizumabe, derivada do estudo AFFIRM (Hutchinson et al, 2009), igual a 0,28, e outra para a população em uso de qualquer medicamento disponível em primeira linha no SUS, conforme Protocolos Clínicos e Diretrizes Terapêuticas (PCDT).…”